Virios Therapeutics initiated with a Buy rating, $1 price target at Maxim

As previously reported, Maxim initiated coverage of Virios Therapeutics with a Buy rating and $1 price target. Virios is developing IMC-2, a combination of the antiviral valacyclovir and the NSAID celecoxib, and IMC-1, a combination of famciclovir and celecoxib, for Long COVID and fibromyalgia, respectively, noted the firm, which adds that the company has a Phase 3 plan aligned with FDA for fibromyalgia, which it believes “should attract a partner.” Data continues to emerge suggesting these diseases, as well as others characterized by fatigue, pain, balance issues, and other negative symptoms, may be driven by the reactivation of latent viruses, the analyst added.